Michael Pavlides
Overview
Explore the profile of Michael Pavlides including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1833
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Novak A, Acharya A, Beer S, Espinosa A, Smith G, Saga C, et al.
BMC Gastroenterol
. 2025 Feb;
25(1):72.
PMID: 39930378
Background: Patients with suspected acute gallstone disease typically undergo abdominal ultrasound. MRCP is often used for patients with abnormal LFTs, potentially making ultrasound unnecessary for this group. Despite high inter-reader...
2.
Vali Y, Dijk A, Lee J, Boursier J, Ratziu V, Yunis C, et al.
Liver Int
. 2025 Jan;
45(2):e16240.
PMID: 39865358
Background And Aims: The performance of non-invasive liver tests (NITs) is known to vary across settings and subgroups. We systematically evaluated whether the performance of three NITs in detecting advanced...
3.
Feng G, Mozes F, Ji D, Treeprasertsuk S, Okanoue T, Shima T, et al.
Clin Gastroenterol Hepatol
. 2024 Oct;
PMID: 39362618
Background & Aims: Metabolic dysfunction-associated steatohepatitis (MASH) and fibrotic MASH are significant health challenges. This multi-national study aimed to validate the acMASH index (including serum creatinine and aspartate aminotransferase concentrations)...
4.
Khanna K, Barnes E, Benselin J, Culver E, Irving W, Innes H, et al.
BMJ Open
. 2024 Oct;
14(10):e085541.
PMID: 39353693
Introduction: Hepatocellular carcinoma (HCC) is the fastest-rising and fourth most common cause of cancer death worldwide. Liver cirrhosis is the largest underlying risk factor for HCC. Therefore, patients with cirrhosis...
5.
Mozes F, Lee J, Vali Y, Selvaraj E, Jayaswal A, Boursier J, et al.
Liver Int
. 2024 Apr;
44(8):1872-1885.
PMID: 38573034
Background & Aims: There is a need to reduce the screen failure rate (SFR) in metabolic dysfunction-associated steatohepatitis (MASH) clinical trials (MASH+F2-3; MASH+F4) and identify people with high-risk MASH (MASH+F2-4)...
6.
Pavlides M, Mozes F
J Magn Reson Imaging
. 2024 Mar;
60(4):1689-1690.
PMID: 38553874
No abstract available.
7.
McTeer M, Applegate D, Mesenbrink P, Ratziu V, Schattenberg J, Bugianesi E, et al.
PLoS One
. 2024 Feb;
19(2):e0299487.
PMID: 38421999
Aims: Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) outcomes such as MASH (metabolic dysfunction associated steatohepatitis), fibrosis and cirrhosis are ordinarily determined by resource-intensive and invasive biopsies. We aim to...
8.
Qadri S, Vartiainen E, Lahelma M, Porthan K, Tang A, Idilman I, et al.
JHEP Rep
. 2023 Dec;
6(1):100928.
PMID: 38089550
Background & Aims: Pathologists quantify liver steatosis as the fraction of lipid droplet-containing hepatocytes out of all hepatocytes, whereas the magnetic resonance-determined proton density fat fraction (PDFF) reflects the tissue...
9.
Watson A, Petitjean L, Petitjean M, Pavlides M
Liver Int
. 2023 Nov;
44(2):399-410.
PMID: 38010988
Background & Aims: Digital pathology image analysis can phenotype liver fibrosis using histological traits that reflect collagen content, morphometry and architecture. Here, we aimed to calculate fibrosis severity scores to...
10.
Pavlides M, Mozes F, Akhtar S, Wonders K, Cobbold J, Tunnicliffe E, et al.
Contemp Clin Trials
. 2023 Oct;
134:107352.
PMID: 37802221
Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of the metabolic syndrome with global prevalence reaching epidemic levels. Despite the high disease burden in the population only a small...